ClinicalTrials.gg
RecruitingNCT07330258PORTRAITUpdated Nov 20, 2026

A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite Taking Parkinson's Medications

An observational study in Parkinson's Disease, sponsored by Bayer. Recruiting at 27 sites in United States. Open to participants aged 45 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Bayer · Observational

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Nov 20, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
45 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Parkinson Disease by Bayer — 6 open to participants now, 8 under way, 1 of them phase 3. Parkinson Disease · Bayer.

Started
2026
with 1 other
Observational
5 of 12
3 open now
Registered
11th of 12
by date

Among the 12 studies in Parkinson Disease by Bayer, this one is one of 2 that started in 2026, is one of 5 observational ones, and was the 11th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

6 of the 12 studies in Parkinson Disease by Bayer are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 45 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Parkinson Disease by Bayer, or all of them as a file.
02

Study summary

This is an observational study in which data are collected and studied from Parkinson's disease patients who have movement symptoms despite taking standard Parkinson's medications. In observational studies, observations are made without any changes to the participant's healthcare or treatment plan. No investigational product will be administered in this study, as participants will be treated with the standard of care that medical experts currently consider most appropriate.

Parkinson's disease (PD) is a condition that affects the brain and causes problems with movement and other body functions. The symptoms of Parkinson's disease can worsen over time. People with Parkinson's disease may experience shaking (tremor), slow movements, stiff muscles, trouble walking, and problems with balance. They can also have other symptoms, such as difficulty thinking clearly, changes in mood, or difficulty sleeping. Parkinson's disease mostly affects older adults, but it can happen to younger people too. There is no cure, but treatments can help manage the symptoms and improve quality of life.

While doctors and researchers know that Parkinson's disease affects people in different ways and can worsen over time, there are still many things they don't fully understand-especially for people who experience movement symptoms despite taking their usual Parkinson's medicines. Earlier studies did not follow these patients long enough or collect all the important information needed. This study is being done to fill those gaps.

The main purpose of this study is to better understand how Parkinson's disease changes over time in patients who experience movement symptoms while taking standard oral Parkinson's medications, what challenges patients and their care partners face, and how their treatments are working in real life. To do this, researchers will collect data on:

  • Sociodemographics (e.g. age, gender, race/ethnicity, insurance provider).
  • Medical history and vital signs (e.g. comorbidities, family history of Parkinson's, height, weight, blood pressure).
  • Medications and treatments (e.g. Parkinson's and non-Parkinson's medications and other treatments, rehabilitation therapy sessions, use of mobility assistance devices).
  • Movement symptoms (e.g. tremor, slow movement, balance).
  • Non-movement symptoms (e.g. cognition, mood, sleep, activities of daily living).
  • Molecular data (e.g. genetics, α-synuclein).
  • Burden of care (e.g. economic cost).

Data will come from questionnaires or rating scales conducted by the doctor with the patient during study visits, diaries and logs completed by the patient, medical records, health insurance claims records, blood samples and skin biopsies, a digital device that records movement/non-movement symptoms, and questionnaires completed by the care partner.

Data will be collected from December 2025 to December 2032. Each participant may be followed for up to 5 years.

03

Conditions studied

  • Parkinson's Disease

Browse trials for

Keywords

  • Natural history study
  • Parkinson's disease
  • PD Motor (Hauser) Diary
  • MDS-UPDRS
  • Electronic health/medical records
  • Administrative claims data
  • Biological samples
  • Digital health technology
  • Care partner
04

Who can participate

Ages eligible
45 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with Parkinson's disease experiencing motor complications while on antiparkinsonian medications

Eligibility criteria

Inclusion Criteria for Patient:

  • Individual of any sex ≥45 to ≤75 years of age at (at least 30% ≤60 years of age).
  • Diagnosis of clinically established Parkinson's disease (PD) as defined by the Movement Disorder Society (MDS) Clinical Diagnostic Criteria for PD ≥4 and \<12 years from time of PD diagnosis at informed consent.
  • Modified H\&Y stage II-III in the practically defined OFF-medication state (≥12 hours from last dose of antiparkinsonian medications).
  • Score of ≥30 on MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III in the OFF-medication state.
  • Presence of motor fluctuations with ≥1 hour of absolute time in the OFF state per day as assessed by clinician/patient at screening.
  • Receiving stable antiparkinsonian medication regimen for ≥4 weeks prior to screening with a levodopa daily dose ≥300 mg or a dosing frequency of ≥3 times per day.
  • Responsiveness to levodopa as determined by change in the following measures from the practically defined OFF state to ON state after taking typical first-daily dose of PD-medications: i. any degree of improvement (≥0.5 point) in modified H\&Y stage OR. ii. ≥30% improvement in MDS-UPDRS part III score.
  • (MoCA) score of ≥24.
  • Agree to participate and provide signed informed consent.

Exclusion Criteria for Patient:

  • Known history or presence of conditions that may provide an alternative to a PD diagnosis including but not limited to: multiple system atrophy, progressive supranuclear palsy, striatonigral degeneration, corticobasal syndrome/degeneration, vascular Parkinsonism, drug-induced Parkinsonism, essential tremor, diffuse Lewy body disease, Lewy body dementia, Huntington's disease, Wilson's disease, Fahr's disease, Alzheimer's disease, cerebrovascular disease, brain tumor, trauma, and infection.
  • Known history or presence of significant vascular and/or cardiovascular disease limited to: stroke, , poorly controlled hypertension, poorly controlled diabetes, unstable angina pectoris, or unstable myocardial infarction.
  • Known history or presence of significant psychosis or impulse control disorder, or untreated or sub optimally treated depression.
  • Known history or presence of , virus, virus, syphilis, or tuberculosis.
  • Current or previously active malignant disease within the past 5 years, except definitively treated cutaneous squamous cell carcinoma, basal cell carcinoma, or in situ uterine cervical carcinoma.
  • Currently pregnant, nursing, lactating, breastfeeding, or plan to be during study duration.
  • Known history or current use of percutaneous levodopa/carbidopa intestinal gel, subcutaneous levodopa, or apomorphine pump.
  • Prior history of brain surgery, including but not limited to: deep brain stimulation (DBS), pallidotomy, focused ultrasound thalamotomy, or other experimental neurosurgical procedure.
  • Known history or current participation in cell or gene therapy procedures.
  • Current participation in any interventional clinical trial.

Inclusion Criteria for Care Partner:

  • ≥18 years of age at informed consent.
  • Identified by the PD patient as their primary care partner.
  • Agree to participate and the ability to provide signed informed consent independently, without the need for a legal representative.

Exclusion Criteria for Care Partner:

  • Not applicable.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Parkinson's Disease Cohort

    A single cohort of patients with Parkinson's disease experiencing motor complications while receiving standard-of-care oral therapies. The care partner of the patient may also participate in the study.

    Other: Standard of Care

  • Care Partners Cohort

    The care partner of the patient may also participate in the study.

Interventions

  • OtherStandard of Care

    Follow clinical practice/administration. No investigational products will be administered in this study. Patients will be treated in accordance with standard of care as determined by their clinician.

06

What researchers measure

Primary outcomes

  1. Descriptive summary of motor outcomes among Parkinson's disease patients treated with oral antiparkinsonian medications who experience motor complications.

    This outcome will be assessed using Parkinson's disease (PD) Motor (Hauser) Diary, Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts II-IV (each part has several items scored from 0-normal to 4-severe; with higher scores indicating greater impairment), modified Hoehn \& Yahr (stages Parkinson's disease severity from 1 \[unilateral involvement only\] to 5 \[wheelchair-bound or bedridden unless aided\]), Universal Dyskinesia Rating Scale (UDysRS) (items scored from 0-none to 4-severe; higher scores indicate more severe dyskinesia), medical records, and digital health technology.

    Time frame: From baseline up to 5 years

  2. Descriptive summary of non-motor outcomes among Parkinson's disease patients treated with oral antiparkinsonian medications who experience motor complications.

    This outcome will be assessed using Montreal Cognitive Assessment (MoCA, score 0-30, higher = better cognition), MDS-UPDRS I (4-point scale, higher = greater impairment), modified Schwab \& England Activities of Daily Living (0-100%, higher = greater independence), MDS Non-Motor Rating Scale (MDS-NMS, 4-point scale, higher = more severe non-motor symptoms), Parkinson's Disease Questionnaire-39 (PDQ-39, 0-100 scale, higher = worse quality of life), Parkinson's Disease Health Index (PD-HI, higher = worse health status), Parkinson's Disease Sleep Scale 2 (PDSS-2, 4-point scale, higher = more severe sleep problems), Clinical Global Impressions Severity (CGI-S, 7-point scale, higher = greater severity of illness), Patient Global Impression Severity (PGI-S, 7-point scale, higher = greater severity), EuroQoL 5-Dimension 5-Level (EQ-5D-5L, 5 dimensions, 5 levels, plus visual analogue scale (VAS) 0-100 \[100=best imaginable health\]), medical records, and digital health technology.

    Time frame: From baseline up to 5 years

  3. Descriptive summary of Parkinson's medications and treatments received

    This outcome will be assessed by the logs (Parkinson's medications, Parkinson's advanced therapies, rehabilitation therapies \& mobility assistance devices) completed by the patient, medical records, and health insurance claims records.

    Time frame: From baseline up to 5 years

  4. Descriptive summary on the burden of care - psychological dimension

    This outcome will be assessed using the Zarit Burden Interview (ZBI), a 22-item questionnaire scored 0-88 (higher scores indicate greater burden).

    Time frame: From baseline up to 5 years

  5. Descriptive summary on the burden of care - economic dimension

    This outcome will be assessed using the Caregiver Indirect and Informal Care Cost Assessment Questionnaire (CIIQ), which includes 13 questions on work status, productivity, and informal care costs.

    Time frame: From baseline up to 5 years

07

Study locations

15 of 27 sites recruiting
  • Banner Alzheimer's Institute (BAI)-Phoenix
    Phoenix, Arizona 85006, United States
    Recruiting
  • University of Arizona - Movement Disorder Clinic
    Tucson, Arizona 85719, United States
    Recruiting
  • The Parkinson's & Movement Disorder Institute
    Fountain Valley, California 92708, United States
    Recruiting
  • Keck School of Medicine
    Los Angeles, California 90033, United States
    Recruiting
  • Yale School of Medicine's Stephen and Denise Adams Center for Parkinson's Disease Research
    New Haven, Connecticut 06510, United States
    Not yet recruiting
  • Baptist Health Miami Neuroscience Institute
    Miami, Florida 33176, United States
    Recruiting
  • AdventHealth Neuroscience Institute
    Orlando, Florida 32804, United States
    Not yet recruiting
  • University of South Florida
    Tampa, Florida 33612, United States
    Recruiting
  • Morehouse Healthcare
    Atlanta, Georgia 30310, United States
    Not yet recruiting
  • Medical College of Georgia at Augusta University
    Augusta, Georgia 30912, United States
    Recruiting
  • Northwestern Memorial HealthCare at Central DuPage Hospital
    Winfield, Illinois 60190, United States
    Recruiting
  • MedStar Montgomery Medical Center
    Olney, Maryland 20832, United States
    Recruiting
  • Boston Medical Center
    Boston, Massachusetts 02215, United States
    Not yet recruiting
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
    Recruiting
  • Rutgers - Robert Wood Johnson Medical School
    New Brunswick, New Jersey 08901, United States
    Not yet recruiting
  • Northwell Health
    New York, New York 10016, United States
    Recruiting
  • Stony Brook University
    Stony Brook, New York 11794, United States
    Not yet recruiting
  • University of Buffalo Jacobs School of Medicine
    Williamsville, New York 14203, United States
    Recruiting
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
    Not yet recruiting
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
    Not yet recruiting
  • Baylor College of Medicine
    Houston, Texas 77030, United States
    Not yet recruiting
  • University of Texas Health Science Center at Houston
    Houston, Texas 77030, United States
    Not yet recruiting
  • Intermountain Health
    Murray, Utah 84107, United States
    Recruiting
  • University of Vermont
    Burlington, Vermont 05402, United States
    Recruiting
  • University of Virginia
    Charlottesville, Virginia 22903, United States
    Recruiting
  • Sentara Neurology Specialists
    Norfolk, Virginia 23510, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • VA Puget Sound Health Care System
    Seattle, Washington 98108, United States
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: No — Currently, there is no established plan for the sharing of Individual Patient Data (IPD) from this study. The availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA 'Principles for responsible clinical trial data sharing.' This pertains to the scope, timepoint, and process of data access. As such, Bayer commits to considering requests from qualified researchers for patient- / study-level clinical trial data, and documents from clinical trials involving medicines and indications approved in the US and EU. However, this commitment does not reflect an active IPD sharing plan. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Researchers can use www.vivli.org to request access to IPD and documents from clinical studies to conduct research. Information on Bayer's criteria for listing studies is provided in the member section of the portal.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Dec 2032, 77 months after the start.

Of 60 industry-sponsored observational studies under Parkinson Disease, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 64. This study's planned 77 months is above that.

Counting every sponsor, half of 441 studies reached it within 47 months; a quarter within 22 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2025
First posted
Jan 9, 2026
StartActual
Jul 21, 2026
Primary completionEst.
Dec 21, 2032
CompletionEst.
Jun 1, 2033
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
8 sites changed recruiting status (8 now recruiting)
Show 8 sites
  • University of Arizona - Movement Disorder Clinic · Tucson, United StatesNot yet recruiting→Recruiting
  • University of South Florida · Tampa, United StatesNot yet recruiting→Recruiting
  • Northwestern Memorial HealthCare at Central DuPage Hospital · Winfield, United StatesNot yet recruiting→Recruiting
  • MedStar Montgomery Medical Center · Olney, United StatesNot yet recruiting→Recruiting
  • University of Michigan · Ann Arbor, United StatesNot yet recruiting→Recruiting
  • Northwell Health · New York, United StatesNot yet recruiting→Recruiting
  • Intermountain Health · Murray, United StatesNot yet recruiting→Recruiting
  • University of Vermont · Burlington, United StatesNot yet recruiting→Recruiting
Nov 20, 2026
Show all 2 updates
  1. Nov 20, 2026
    8 sites changed recruiting status (8 now recruiting)
    Show 8 sites
    • University of Arizona - Movement Disorder Clinic · Tucson, United StatesNot yet recruiting→Recruiting
    • University of South Florida · Tampa, United StatesNot yet recruiting→Recruiting
    • Northwestern Memorial HealthCare at Central DuPage Hospital · Winfield, United StatesNot yet recruiting→Recruiting
    • MedStar Montgomery Medical Center · Olney, United StatesNot yet recruiting→Recruiting
    • University of Michigan · Ann Arbor, United StatesNot yet recruiting→Recruiting
    • Northwell Health · New York, United StatesNot yet recruiting→Recruiting
    • Intermountain Health · Murray, United StatesNot yet recruiting→Recruiting
    • University of Vermont · Burlington, United StatesNot yet recruiting→Recruiting
  2. Nov 18, 2026
    Minor edits only
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07330258
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jan 9, 2026
Start date
Jul 21, 2026
Primary completion
Dec 21, 2032 (estimated)
Completion
Jun 1, 2033 (estimated)
Last update
Nov 20, 2026

Study contacts

Bayer Clinical Trials Contact
Contact
clinical-trials-contact@bayer.com
(+)1-888-84 22937

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion